The Food and Drug Administration on Friday approved a generic version of Daraprim, the anti-infective treatment made famous when Martin Shkreli’s company raised its price by more than 5,000%.
The approval means Shkreli’s company, now called Phoenixus, will no longer have a monopoly on Daraprim, which lost patent protection years ago. Cerovene, a U.S. generics company, will market an identical product.
About the Author Reprints
